Cryoprecipitate is prepared from fresh frozen plasma by slow controlled thawing at 4 to 6 °C. The resulting precipitate is separated from the supernatant and refrozen for storage. Cryoprecipitate contains factor VIII, von Willebrand factor, fibrinogen, factor XIII, and fibronectin in higher concentrations than is found in fresh frozen plasma. For these reasons it used to be the mainstay of treatment for hemophilia A and von Willebrand's disease, but it has been superseded by virally inactivated pooled factor concentrates. The same guidelines as for administration of fresh frozen plasma apply for cryoprecipitate and it carries a similar risk of transmission of infection. The dose for one transfusion is 10 to 30 units depending on the circumstances.
Was this article helpful?